Under the proposal, price reductions offered by drugmakers to PBMs, Medicare Part D and managed care plans would not receive safe harbor protection as “discounts.” Those rebates could be subject to prosecution under the Anti-Kickback Statute.
HHS suggests getting rid of safe harbors for Part D drug rebates
